Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs

Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic platform against a range of cancer indications, emerged from stealth today with $20 million in seed financing. Backed by multiple investors including Playground Global and Godfrey Capital, the company is focused on moving its first therapeutic into clinical trials next year.